New antibiotic cocktail takes on superbugs in phase 3 trial

NCT ID NCT05905055

Completed Disease control Sponsor: Meiji Seika Pharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two new antibiotic combinations (cefepime/nacubactam and aztreonam/nacubactam) against the best available treatments for adults with serious infections like urinary tract infections, pneumonia, and abdominal infections caused by carbapenem-resistant bacteria. The trial enrolled 126 participants and compared how well each treatment worked and how safe it was. The goal was to see if these new combinations could successfully treat these hard-to-kill infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cefepime/nacubactam and aztreonam/nacubactam (antibiotic combinations)
What this could lead to: If successful, this could provide new treatment options for serious infections that are resistant to many current antibiotics.
What could go wrong: This is a relatively small phase 3 trial (126 participants) and results may not apply to all patients. The new drug combinations may not work better than existing therapies and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute pyelonephritis bacterial urinary tract infection infectious peritonitis nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PYELONEPHRITIS COMPLICATED INTRA-ABDOMINAL INFECTION COMPLICATED URINARY TRACT INFECTION HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA

Contacts and locations

Locations

Meiji Research Site

Changsha, China
Meiji Research Site

Chongqing, China
Meiji Research Site

Fuyang, China
Meiji Research Site

Guangzhou, China
Meiji Research Site

Hangzhou, China
Meiji Research Site

Hefei, China
Meiji Research Site

Nanjing, China
Meiji Research Site

Nanning, China
Meiji Research Site

Quanzhou, China
Meiji Research Site

Shanghai, China
Meiji Research Site

Shenzhen, China
Meiji Research Site

Shijiazhuang, China
Meiji Research Site

Wuxi, China
Meiji Research Site

Xuzhou, China
Meiji Research Site

Zagreb, Croatia
Meiji Research Site

Kyjov, Czechia
Meiji Research Site

Limoges, France
Meiji Research Site

Nîmes, France
Meiji Research Site

Paris, France
Meiji Research Site

Strasbourg, France
Meiji Research Site

Kutaisi, Georgia
Meiji Research Site

Tbilisi, Georgia
Meiji Research Site

Zestaponi, Georgia
Meiji Research Site

Athens, Greece
Meiji Research Site

Be’er Ya‘aqov, Israel
Meiji Research Site

Ramat Gan, Israel
Meiji Research Site

Tel Aviv, Israel
Meiji Research Site

Nankoku, Kochi, Japan
Meiji Research Site

Hiroshima, Japan
Meiji Research Site

Kanazawa, Japan
Meiji Research Site

Nagasaki, Japan
Meiji Research Site

Nankoku, Japan
Meiji Research Site

Ōta-ku, Japan
Meiji Research Site

Shinjuku-ku, Japan
Meiji Research Site

Toyoake, Japan
Meiji Research Site

Daugavpils, Latvia
Meiji Research Site

Liepāja, Latvia
Meiji Research Site

Riga, Latvia
Meiji Research Site

Valmiera, Latvia
Meiji Research Site

Nitra, Slovakia
Meiji Research Site

Svidník, Slovakia
Meiji Research Site

Córdoba, Spain
Meiji Research Site

Madrid, Spain
Meiji Research Site

Kaohsiung City, Taiwan
Meiji Research Site

Taichung, Taiwan
Meiji Research Site

Taipei, Taiwan
Meiji Research Site

Bangkok, Thailand
Meiji Research Site

Chiang Mai, Thailand
Meiji Research Site

Khon Kaen, Thailand
Meiji Research Site

Ankara, Turkey (Türkiye)
Meiji Research Site

Eskişehir, Turkey (Türkiye)
Meiji Research Site

Istanbul, Turkey (Türkiye)
Meiji Research Site

İzmit, Turkey (Türkiye)
Meiji Research Site

Trabzon, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.